Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v7-EN
Language French English
Date Updated 2022-05-09 2022-05-09
Drug Identification Number 02474719 02474719
Brand name PENTHROX PENTHROX
Common or Proper name Methoxyflurane Volatile liquid for inhalation Methoxyflurane Volatile liquid for inhalation
Company Name ENDO VENTURES LTD. ENDO VENTURES LTD.
Ingredients METHOXYFLURANE METHOXYFLURANE
Strength(s) 99.9% 99.9%
Dosage form(s) SOLUTION SOLUTION
Route of administration INHALATION INHALATION INHALATION INHALATION
Packaging size 3ml 10's 3ml 10's
ATC code N02BG N02BG
ATC description
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2022-01-12 2022-01-12
Actual start date 2022-01-12 2022-01-12
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments We wish to advise that MDI and Purdue Pharma (Canada) have terminated their commercial arrangement respecting the distribution of Penthrox® (methoxyflurane) in Canada. MDI is transitioning the distribution rights for Penthrox® to a new distributor, namely, Paladin Labs. Paladin Labs will require certain licenses and approvals to distribute Penthrox® in Canada. During the transition process, Penthrox® will not be available in the market for a period of time. Paladin Labs will provide further communication to keep you informed as the transition progresses and as stock becomes readily available. We apologize for any inconvenience and thank you for your on-going support of Penthrox®. We wish to advise that MDI and Purdue Pharma (Canada) have terminated their commercial arrangement respecting the distribution of Penthrox® (methoxyflurane) in Canada. MDI is transitioning the distribution rights for Penthrox® to a new distributor, namely, Paladin Labs. Paladin Labs will require certain licenses and approvals to distribute Penthrox® in Canada. During the transition process, Penthrox® will not be available in the market for a period of time. Paladin Labs will provide further communication to keep you informed as the transition progresses and as stock becomes readily available. We apologize for any inconvenience and thank you for your on-going support of Penthrox®.
Health Canada comments